28003511|t|Tobacco Consumption and Toxicant Exposure of Cigarette Smokers Using Electronic Cigarettes
28003511|a|There is considerable debate about the benefits and risks of electronic cigarettes (ECs). To better understand the risk-benefit ratio of ECs, more information is needed about net nicotine consumption and toxicant exposure of cigarette smokers switching to ECs. Forty cigarette smokers (>1 year of smoking) interested in switching to ECs but not necessarily quitting smoking were enrolled in a four- week observational study and provided an e-Go C non-variable battery and refillable atomizers and choice of 8 flavors in 12 or 24 mg nicotine dosage. Measurement of urinary cotinine (metabolite of nicotine), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL; a pulmonary carcinogen), and eight volatile organic compounds (VOCs) that are toxic tobacco smoke constituents was conducted at baseline and Week -4. All participants with follow-up data (92.5%) reported using the study EC. Of the 40 smokers, 16 reported no cigarettes at Week -2 (40%) and 6 continued to report no cigarettes at Week -4 (15%). Change in nicotine intake over the 4- weeks was non-significant (p=0.90). Carbon monoxide (p<0.001), NNAL (p<0.01) and metabolites of benzene (p < 0.01) and acrylonitrile (p=0.001) were significantly decreased in the study sample. Smokers switching exclusively to ECs for at least half of the study period demonstrated significant reductions in HEMA (p>=0.03) and AAMA (p<0.01). Smokers using ECs over 4- weeks maintained cotinine levels and experienced significant reductions in carbon monoxide, NNAL, and two out of eight measured VOC metabolites. Those who switched exclusively to ECs for at least half of the study period significantly reduced two additional VOCs. This study extends current literature by measuring change in smoking dependence and disease-associated biomarkers, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and a panel of eight common volatile organic compounds (VOCs) that are toxic tobacco smoke constituents in smokers who switch to electronic cigarettes. The findings support the idea of harm reduction, however some levels of toxicant exposure are still of clinical concern, particularly for dual users. Extrapolation of these results must be careful to separate the different toxic exposure results for exclusive switchers versus dual cigarette + EC users, and not to equate harm reduction with the idea that using ECs is harmless.
28003511	55	62	Smokers	T033	UMLS:C0337664
28003511	69	90	Electronic Cigarettes	T074	UMLS:C3849993
28003511	152	173	electronic cigarettes	T074	UMLS:C3849993
28003511	175	178	ECs	T074	UMLS:C3849993
28003511	228	231	ECs	T074	UMLS:C3849993
28003511	270	278	nicotine	T103	UMLS:C0028040
28003511	326	333	smokers	T033	UMLS:C0337664
28003511	347	350	ECs	T074	UMLS:C3849993
28003511	368	375	smokers	T033	UMLS:C0337664
28003511	397	407	interested	T038	UMLS:C0543488
28003511	424	427	ECs	T074	UMLS:C3849993
28003511	495	514	observational study	T062	UMLS:C1518527
28003511	563	583	refillable atomizers	T074	UMLS:C0004185
28003511	623	631	nicotine	T103	UMLS:C0028040
28003511	640	671	Measurement of urinary cotinine	T058	UMLS:C1278256
28003511	673	683	metabolite	T103	UMLS:C0870883
28003511	687	695	nicotine	T103	UMLS:C0028040
28003511	698	743	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol	T103	UMLS:C0389836
28003511	745	749	NNAL	T103	UMLS:C0389836
28003511	753	762	pulmonary	T017	UMLS:C0024109
28003511	763	773	carcinogen	T103	UMLS:C0007090
28003511	786	812	volatile organic compounds	T103	UMLS:C2350439
28003511	814	818	VOCs	T103	UMLS:C2350439
28003511	835	842	tobacco	T103	UMLS:C0040329
28003511	843	848	smoke	T103	UMLS:C0037366
28003511	905	917	participants	T098	UMLS:C0679646
28003511	923	932	follow-up	T058	UMLS:C1522577
28003511	965	970	study	T062	UMLS:C2603343
28003511	971	973	EC	T074	UMLS:C3849993
28003511	985	992	smokers	T033	UMLS:C0337664
28003511	1105	1113	nicotine	T103	UMLS:C0028040
28003511	1169	1184	Carbon monoxide	T103	UMLS:C0007018
28003511	1196	1200	NNAL	T103	UMLS:C0389836
28003511	1214	1225	metabolites	T103	UMLS:C0870883
28003511	1229	1236	benzene	T103	UMLS:C0005036
28003511	1252	1265	acrylonitrile	T103	UMLS:C0001223
28003511	1312	1317	study	T062	UMLS:C2603343
28003511	1326	1333	Smokers	T033	UMLS:C0337664
28003511	1359	1362	ECs	T074	UMLS:C3849993
28003511	1388	1393	study	T062	UMLS:C2603343
28003511	1474	1481	Smokers	T033	UMLS:C0337664
28003511	1488	1491	ECs	T074	UMLS:C3849993
28003511	1517	1532	cotinine levels	T058	UMLS:C0202363
28003511	1575	1590	carbon monoxide	T103	UMLS:C0007018
28003511	1592	1596	NNAL	T103	UMLS:C0389836
28003511	1592	1596	NNAL	T103	UMLS:C0389836
28003511	1628	1631	VOC	T103	UMLS:C2350439
28003511	1632	1643	metabolites	T103	UMLS:C0870883
28003511	1679	1682	ECs	T074	UMLS:C3849993
28003511	1708	1713	study	T062	UMLS:C2603343
28003511	1758	1762	VOCs	T103	UMLS:C2350439
28003511	1769	1774	study	T062	UMLS:C2603343
28003511	1783	1801	current literature	T170	UMLS:C0023866
28003511	1833	1843	dependence	T038	UMLS:C0439857
28003511	1848	1877	disease-associated biomarkers	T201	UMLS:C0005516
28003511	1879	1924	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol	T103	UMLS:C0389836
28003511	1926	1930	NNAL	T103	UMLS:C0389836
28003511	1960	1986	volatile organic compounds	T103	UMLS:C2350439
28003511	1988	1992	VOCs	T103	UMLS:C2350439
28003511	2009	2016	tobacco	T103	UMLS:C0040329
28003511	2017	2022	smoke	T103	UMLS:C0037366
28003511	2039	2046	smokers	T033	UMLS:C0337664
28003511	2061	2082	electronic cigarettes	T074	UMLS:C3849993
28003511	2117	2131	harm reduction	T058	UMLS:C0679771
28003511	2378	2380	EC	T074	UMLS:C3849993
28003511	2406	2420	harm reduction	T058	UMLS:C0679771
28003511	2446	2449	ECs	T074	UMLS:C3849993